FGFR Signaling as a Candidate Therapeutic Target for Cancers Resistant to Carbon Ion Radiotherapy
Authors:
- Narisa Dewi Maulany DarwisNDNarisa Dewi Maulany Darwis
- Ankita NachankarANAnkita Nachankar
- Yasushi SasakiYasushi Sasaki
- Toshiaki MatsuiTMToshiaki Matsui
- Shin-Ei NodaSNShin-Ei Noda
- Kazutoshi MurataKMKazutoshi Murata
- Tomoaki TamakiTTTomoaki Tamaki
- Ken AndoKAKen Ando
- Noriyuki OkonogiNONoriyuki Okonogi
- Shintaro ShibaSSShintaro Shiba
- Daisuke IrieDIDaisuke Irie
- Takuya KaminumaTKTakuya Kaminuma
Open Access
- 14 September 2019
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 20 (18) , 4563
Abstract
Radiotherapy is an essential component of cancer therapy. Carbon ion radiotherapy (CIRT) promises to improve outcomes compared with standard of care in many cancers. Nevertheless, clinicians often observe in-field recurrence after CIRT. This indicates the presence of a subset of cancers that harbor intrinsic resistance to CIRT. Thus, the development of methods to identify and sensitize CIRT-resistant cancers is needed. To address this issue, we analyzed a unique donor-matched pair of clinical specimens: a treatment-naïve tumor, and the tumor that recurred locally after CIRT in the same patient. Exon sequencing of 409 cancer-related genes identified enrichment of somatic mutations in FGFR3 and FGFR4 in the recurrent tumor compared with the treatment-naïve tumor, indicating a pivotal role for FGFR signaling in cancer cell survival through CIRT. Inhibition of FGFR using the clinically available pan-FGFR inhibitor LY2874455 sensitized multiple cancer cell lines to carbon ions at 3 Gy (RBE: relative biological effectiveness), the daily dose prescribed to the patient. The sensitizer enhancement ratio was 1.66 ± 0.17, 1.27 ± 0.09, and 1.20 ± 0.18 in A549, H1299, and H1703 cells, respectively. Our data indicate the potential usefulness of the analytical pipeline employed in this pilot study to identify targetable mutations associated with resistance to CIRT, and of LY21874455 as a sensitizer for CIRT-resistant cancers. The results warrant validation in larger cohorts.Keywords
This publication has 27 references indexed in Scilit:
- Phase I Study of Carbon Ion Radiotherapy and Image-Guided Brachytherapy for Locally Advanced Cervical CancerCancers, 2018
- Simultaneous evolutionary expansion and constraint of genomic heterogeneity in multifocal lung cancerNature Communications, 2017
- Charged-particle therapy in cancer: clinical uses and future perspectivesNature Reviews Clinical Oncology, 2017
- Integrated genomic and molecular characterization of cervical cancerNature, 2017
- Tumour heterogeneity and the evolution of polyclonal drug resistanceMolecular Oncology, 2014
- Landscape of genomic alterations in cervical carcinomasNature, 2013
- Comparison of the effects of photon versus carbon ion irradiation when combined with chemotherapy in vitroRadiation Oncology, 2013
- Mutational heterogeneity in cancer and the search for new cancer-associated genesNature, 2013
- Past, present, and future of radiotherapy for the benefit of patientsNature Reviews Clinical Oncology, 2012
- Mutation of the PIK3CA oncogene in human cancersBritish Journal of Cancer, 2006